Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.02
+$0.0219 · +2.19%
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Previous close
$1.02
+$0.0219 · +2.19%
Pre-market
$1.02
$0.00 · 0.00%
Oct 8, 4:46 AM ET
Regular session · ET · Market data may be delayed.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Day range
Current $1.02
52-week range
Current $1.02
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
67
Bullish
Risk
61
High Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Day range
Current $1.02
52-week range
Current $1.02
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 850K USD | — | — | — |
| Cost of goods sold | 1.47M USD | — | — | — | — |
| Gross profit | −1.47M USD | 850K USD | — | — | — |
| Research and development | 55.97M USD | 42.34M USD | 38.12M USD | 30M USD | 20.34M USD |
| Selling, general, and administrative | 16.87M USD | 15.13M USD | 12.24M USD | 11.66M USD | 10.93M USD |
| Operating expenses | 71.37M USD | 57.48M USD | 50.36M USD | 41.66M USD | 81.88M USD |
| Interest income | 6.35M USD | 7.3M USD | 7.9M USD | 2.36M USD | 29K USD |
| Interest expense | — | — | — | 2.36M USD | 370K USD |
| Depreciation and amortization | 1.47M USD | 1.75M USD | 1.89M USD | 1.9M USD | 1.62M USD |
| Operating income | −72.84M USD | −56.63M USD | −50.36M USD | −41.66M USD | −81.88M USD |
| Net income | −66.49M USD | −49.38M USD | −42.49M USD | −39.23M USD | −82.18M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.02M0.00%2.3T USD0.03%$381.03-0.40%
State Street SPDR S&P Biotech ETFXBI5.03M0.05%10.08B USD0.35%$150.23-0.44%
Vanguard Extended Market ETFVXF4.35M0.00%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 ETFIWM3.5M0.00%78.56B USD0.19%$277.7-1.29%
Vanguard Russell 2000 ETFVTWO1.8M0.01%18B USD0.06%$112.21-1.26%
Fidelity Enhanced Small Cap ETFFESM1.62M0.02%6.41B USD0.28%$45.22-1.14%
Vanguard Health Care ETFVHT695.68K0.00%22B USD0.09%$315.31+0.78%
iShares Micro-Cap ETFIWC409.93K0.03%1.33B USD0.60%$183.36-1.09%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
